The Tregs are also increased in CML patients at diagnosis and in patients refractory to TKI treatment, and these Tregs have higher levels of PD-1 expression (67, 68). This evidence concerns the gene PDCD1 and chronic myelogenous leukemia, BCR-ABL1 positive.